Skip to main content
. Author manuscript; available in PMC: 2012 Oct 29.
Published in final edited form as: Eur J Cancer. 2011 Oct 19;48(2):202–208. doi: 10.1016/j.ejca.2011.09.001

Table 3.

The association between pre-treatment neutrophil to lymphocyte ratio and progression free survival and overall survival, by multivariate analysis in patient subgroups.

Subgroup Number
of patients		 Pre-treatment neutrophil to lymphocyte ratio ≤3 versus >3
Median PFS (months); HR, p Median OS (months); HR, p
Heng favourable risk 30 14 versus 7; 0.71, 0.002 Not reached (28) versus 17; 0.54, 0.03
Heng intermediate risk 74 14 versus 4; 0.27, <0.001 Not reached (29) versus 11; 0.65, 0.025
Heng poor risk 24 6 versus 4; 0.85, 0.2 14 versus 13; NS
Patients with clear cell
variety that are naïve
to systemic targeted treatment		 92 13 versus 4; 0.26, <0.001 Not reached (28) versus 13; 0.55, 0.04
Patients not using ASIs 86 11.5 versus 4; 0.287, 0.001 Not reached (29) versus 10 (0.5, 0.04)

ASIs = angiotensin system inhibitors; NS = non-significant; PFS = progression free survival; OS = overall survival.